Abstract 2181P
Background
Immune checkpoint inhibitor (ICIs) has opened a new era in the treatment of malignant tumors, but its clinical application has been severely hindered by various immune-related adverse events. Checkpoint inhibitors pneumonitis (CIP) is one of the most common fatal adverse events.The current guideline-recommended treatment strategies are difficult to achieve precise treatment and efficient coverage of CIP. The optimal timing of ICIs suspension and the initiation and dose of corticosteroids still need to be optimized.
Methods
A total of 121 CIP patients of 672 cancer patients were retrospectively analyzed. The detailed treatment process of CIP patients was recorded. Radiographic changes combined with clinical symptoms classified the outcome of CIP into worsening, stable, and improved.
Results
No association were found between continued ICIs after the diagnosis of CIP and worsened outcome in G1 CIP (p=0.296), but continued ICIs treatment was associated with worse outcomes in G2-4 CIP (p=0.009, adjusted p=0.012). For G2 CIP, prompt corticosteroid treatment is closely related with an improved outcome (p=0.015). Initiating corticosteroid in the acute phase is strongly associated with an improved outcome in G2-4 CIP (p=0.021, adjusted p=0.013). Furthermore, patients in the low-dose corticosteroid group were not only conducive to an improved outcome (p=0.024, adjusted p=0.016), but also reduced the risk of residual irreversible fibrotic lesions in G2-4 CIP (p=0.016, adjusted p=0.018).
Conclusions
For G1 CIP, ICIs may be continued conservatively and its safety is manageable. For G2-4 CIP, ICIs should be terminated and corticosteroid therapy initiated as soon as possible after diagnosis to avoid irreversible damage to lung function. Furthermore, initial low doses of corticosteroids(<1mg/kg/d) appear to be more conducive to favorable outcomes than high doses of corticosteroids.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by Outstanding Youth Project of Shaanxi Province (2020JC-35), Research and development projects in Shaanxi Province (2022ZDLSF04-11), Natural Science Foundation of Shaanxi Province (2022JQ-796), Major project of innovation Fund of Chinese Society of Clinical Oncology-MSD (Y-MSD2020-024), Shaanxi Sanqin Scholars Innovation Team (2021-No. 32), Beijing Science Innovation Medical Development Fund (KC2021-JX-0186-5) and National Natural Science Foundation of China (No. 82272073).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2161P - Organization of hospital pharmaceutical consultations for cancer patients receiving oral anticancer drugs: A nationwide cross-sectional study
Presenter: Florian Slimano
Session: Poster session 07
2162P - Can artificial intelligence provide accurate and reliable answers to cancer patients' questions? Comparison of chatbots based on the ESMO Patient Guide about cancer pain
Presenter: Kadriye Bir Yucel
Session: Poster session 07
2163P - Supportive care in French community pharmacies: OncoPharma certification
Presenter: Jérôme Sicard
Session: Poster session 07
2164P - The impact of cancer patients’ face masks on oxygenation and Co2 retention during treatment
Presenter: Mert Sahin
Session: Poster session 07
2165P - A French overview of electronic patient-reported outcomes use in 2022
Presenter: Melina Hocine
Session: Poster session 07
2166P - Long-term consequences of SARS-CoV-2 infection in cancer patients
Presenter: Yana Debie
Session: Poster session 07
2167P - Are bone targeted agents (BTAs) still useful in times of immunotherapy? The SAKK 80/19 BTA study
Presenter: Michael Mark
Session: Poster session 07
2168P - At-home infusion of immunotherapy for patients with solid tumors: First results from a single-centre program
Presenter: Javier Marco Hernández
Session: Poster session 07
2169P - Immunotherapy-based treatment in elderly cancer patients: A real-world multicenter study
Presenter: Mengye He
Session: Poster session 07
2171P - Incidence of adverse events in patients treated with a combination of immune checkpoint blockers and chemotherapy: A real life cohort
Presenter: Layal Rached
Session: Poster session 07